Arcturus Therape - ARCT STOCK NEWS

Arcturus Therapeutics Holdings announced preclinical results for its vaccine LUNAR®-COV19 (ARCT-021), showing a strong antibody response and 100% protection against SARS-CoV-2 following a single dose vaccination in mice. The study indicates robust neutralizing antibody titers persisting up to day 60, along with significant T cell responses. The clinical study is on track with results expected in Q4 2020. Collaboration with Duke-NUS Medical School enhances credibility, and the company emphasizes the potential of its low-dose, single-shot vaccine approach for COVID-19 mass vaccination.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the successful dosing of all subjects in the first cohort of its Phase 1/2 clinical study for ARCT-021, a self-replicating mRNA vaccine for COVID-19. The study aims to evaluate safety and immunogenicity in younger adults, with clinical data expected in Q4 2020. Preclinical results demonstrated 100% seroconversion after a single low-dose administration, indicating promising efficacy. The vaccine is designed for low-dose, single administration, potentially facilitating mass vaccination efforts against COVID-19.

Arcturus Therapeutics Holdings announced progress in its clinical pipeline, with the initiation of Phase 1/2 studies for its COVID-19 mRNA vaccine candidate, ARCT-021, in collaboration with Duke-NUS Medical School. Dosing of subjects is expected imminently, with initial data anticipated by Q4 2020. Additionally, the Phase 1 study for ARCT-810, targeting ornithine transcarbamylase deficiency, continues. The company successfully raised $280 million in 2020 through equity offerings, enhancing its financial position, boasting a cash balance of $136.1 million as of June 30, 2020.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the appointment of Lance Kurata as Chief Legal Officer, effective August 10, 2020. Formerly a partner at Mintz, Kurata brings extensive expertise in biotechnology law, focusing on transactions and intellectual property, which is critical as Arcturus advances its mRNA therapeutic platform. The company anticipates significant clinical trial data this year for its COVID-19 vaccine candidate ARCT-021 and the investigational therapy ARCT-810 for Ornithine Transcarbamylase deficiency.

Arcturus Therapeutics Holdings Inc. announced the closing of its public offering of 3,753,773 shares at $53.00 each, after the underwriters fully exercised their option for an additional 489,622 shares. The offering generated approximately $200 million in gross proceeds. The funds are designated for the development of the LUNAR-COV19 vaccine, along with advancing other therapeutic programs, early research, and corporate purposes. The offering was made under a shelf registration statement effective since May 2020, with Citigroup, Guggenheim Securities, and Barclays as joint managers.

Arcturus Therapeutics Holdings (NASDAQ: ARCT) announced a public offering of 3,264,151 shares at $53.00 each, aiming to raise approximately $173 million. The gross proceeds will support the development of its LUNAR-COV19 vaccine and other clinical programs. Additionally, an option for underwriters to purchase 489,622 more shares is available. The closing of the offering is expected by July 31, 2020. This follows an effective shelf registration statement filed with the SEC earlier this year.

Arcturus Therapeutics Holdings (Nasdaq: ARCT) has secured a binding term sheet with Israel's Ministry of Health to supply its COVID-19 vaccine candidate, LUNAR-COV19. This makes Israel the second country to reserve this vaccine. The final supply agreement is expected within 30 days, contingent on achieving clinical and regulatory milestones. Arcturus aims to produce hundreds of millions of doses in 2020 and 2021, following successful clinical developments and partnerships, including a recent trial approval in Singapore.

Arcturus Therapeutics Holdings (Nasdaq: ARCT) has received approval from the Singapore Health Sciences Authority to proceed with the Clinical Trial Application for its COVID-19 vaccine candidate, LUNAR-COV19. This vaccine employs the innovative STARR™ mRNA technology, which may elicit strong immune responses at low doses. Initial preclinical data indicates that a single dose can boost antibody levels for 50 days. The upcoming human trial will assess safety and immune response in up to 108 adults, including older adults, marking a significant step in Arcturus’ efforts to develop effective COVID-19 vaccines.

Arcturus Therapeutics (Nasdaq: ARCT) announced the formation of a Vaccine Platform Scientific Advisory Board (SAB) with top experts in virology and vaccine development for its LUNAR-COV19 COVID-19 vaccine program. The SAB's insights aim to enhance the vaccine's development pathway. The company is on track for clinical trials scheduled for summer 2020. Arcturus utilizes innovative self-replicating mRNA technology, potentially requiring only a single low-dose administration for effective immunity. The SAB includes notable figures like former Kansas Governor Jeff Colyer and Duke-NUS professor Ooi Eng Eong.